Matt Cooperberg
@dr-coops.bsky.social
Urologic oncology & epi, focus on #prostatecancer @UCSFcancer @UCSFurology. GU Chief @SFVAMC. All views strictly personal. RT≠E. #🟦
Pinned
Matt Cooperberg
@dr-coops.bsky.social
· Jan 16
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
Reposted by Matt Cooperberg
When #prostatecancer just ain’t cancer.
👀 👇
www.sciencedirect.com/science/arti... Re: Rajal B. Shah et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: doi.org/10.1016/j.eu...
@dr-coops.bsky.social
👀 👇
www.sciencedirect.com/science/arti... Re: Rajal B. Shah et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: doi.org/10.1016/j.eu...
@dr-coops.bsky.social
Re: Rajal B. Shah, Gladell P. Paner, Liang Cheng, et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a ...
www.sciencedirect.com
June 12, 2025 at 12:20 PM
When #prostatecancer just ain’t cancer.
👀 👇
www.sciencedirect.com/science/arti... Re: Rajal B. Shah et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: doi.org/10.1016/j.eu...
@dr-coops.bsky.social
👀 👇
www.sciencedirect.com/science/arti... Re: Rajal B. Shah et al. Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: doi.org/10.1016/j.eu...
@dr-coops.bsky.social
Reposted by Matt Cooperberg
Good concise article on the status of Active Surveillance for Prostate Cancer. As treatment/surveillance becomes more precise, Screening becomes more palatable for Primary Care.
via @dr-coops.bsky.social #MensHealth
cuaj.ca/index.php/jo...
via @dr-coops.bsky.social #MensHealth
cuaj.ca/index.php/jo...
Is update of AS in low-risk prostate cancer in Ontario liked to guideline publication?
| Canadian Urological Association Journal
cuaj.ca
June 3, 2025 at 6:27 PM
Good concise article on the status of Active Surveillance for Prostate Cancer. As treatment/surveillance becomes more precise, Screening becomes more palatable for Primary Care.
via @dr-coops.bsky.social #MensHealth
cuaj.ca/index.php/jo...
via @dr-coops.bsky.social #MensHealth
cuaj.ca/index.php/jo...
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
January 16, 2025 at 11:25 PM
Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
acsjournals.onlinelibrary.wiley.com/doi/epdf/10....
Reposted by Matt Cooperberg
Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020.
https://ja.ma/4042hPZ
https://ja.ma/4042hPZ
December 22, 2024 at 8:00 PM
Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020.
https://ja.ma/4042hPZ
https://ja.ma/4042hPZ
Reposted by Matt Cooperberg
It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...
December 14, 2024 at 12:00 AM
It is with great sadness that we mourn our cherished friend and colleague Felix Feng, MD. Felix was a distinguished physician-scientist and beloved at @ucsfhealth.bsky.social. His vision, dedication, and commitment inspired colleagues, peers everywhere, and patients. cancer.ucsf.edu/in-memoriam-...
Brian Thompson’s assassination is a horrifying and tragic. But maybe something good will come of this renewed conversation about an industry whose _entire_ business model has been based for decades on profiting at the expense of patients and providers.
apple.news/ASy_o_WGXRI6...
apple.news/ASy_o_WGXRI6...
After a shocking shooting, Americans vent feelings about health insurance — NPR
The death of UnitedHealthcare CEO Brian Thompson triggered a deluge of painful stories about health care denials on social media.
apple.news
December 6, 2024 at 2:53 PM
Brian Thompson’s assassination is a horrifying and tragic. But maybe something good will come of this renewed conversation about an industry whose _entire_ business model has been based for decades on profiting at the expense of patients and providers.
apple.news/ASy_o_WGXRI6...
apple.news/ASy_o_WGXRI6...
Great updates from Patrick Hensley and Mark Tyson on the huge and growing array of options for non-muscle-invasive #bladdercancer #SUO24
December 5, 2024 at 5:29 PM
Great updates from Patrick Hensley and Mark Tyson on the huge and growing array of options for non-muscle-invasive #bladdercancer #SUO24
Reposted by Matt Cooperberg
How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...
Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer
This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.
jamanetwork.com
December 3, 2024 at 1:58 PM
How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...
It was great to have the chance to chat with @gabecanales.bsky.social last week about low-risk #prostatecancer and active surveillance
x.com/gabecanales/...
@bluecure.bsky.social
x.com/gabecanales/...
@bluecure.bsky.social
x.com
x.com
November 29, 2024 at 7:43 PM
It was great to have the chance to chat with @gabecanales.bsky.social last week about low-risk #prostatecancer and active surveillance
x.com/gabecanales/...
@bluecure.bsky.social
x.com/gabecanales/...
@bluecure.bsky.social
Reposted by Matt Cooperberg
Happy 76th birthday to 2009 Nobel Prize recipient Elizabeth Blackburn, whose 1984 discovery of telomerase not only demonstrated that cells can use RNA to construct DNA, but has spawned an entire field of biological study.
tinyurl.com/47zp8azb
#WomenInSTEM
#HistSci
#BioSky
🧪
tinyurl.com/47zp8azb
#WomenInSTEM
#HistSci
#BioSky
🧪
Capping the Chromosome: Elizabeth Blackburn and the Discovery of Telomerase
Telomerase is one of those enzymes which just won’t let you come to a settled opinion. When it runs wild, it promotes cancer. But it also protects each and every one of your chromosomes faithfully, ...
tinyurl.com
November 26, 2024 at 4:15 PM
Happy 76th birthday to 2009 Nobel Prize recipient Elizabeth Blackburn, whose 1984 discovery of telomerase not only demonstrated that cells can use RNA to construct DNA, but has spawned an entire field of biological study.
tinyurl.com/47zp8azb
#WomenInSTEM
#HistSci
#BioSky
🧪
tinyurl.com/47zp8azb
#WomenInSTEM
#HistSci
#BioSky
🧪
Reposted by Matt Cooperberg
Good morning! Recommending a number of our early adopters & growing list of #OncSky heavy hitters to follow: @sueyom.bsky.social @andreigoga.bsky.social @dr-coops.bsky.social @drkomanduri.bsky.social @atulbutte.bsky.social @hoperugo.bsky.social @hemedoc.bsky.social and more: bsky.app/profile/did:...
November 25, 2024 at 6:22 PM
Good morning! Recommending a number of our early adopters & growing list of #OncSky heavy hitters to follow: @sueyom.bsky.social @andreigoga.bsky.social @dr-coops.bsky.social @drkomanduri.bsky.social @atulbutte.bsky.social @hoperugo.bsky.social @hemedoc.bsky.social and more: bsky.app/profile/did:...
Reposted by Matt Cooperberg
jamanetwork.com/journals/jam...
#Overtreatment of #prostatecancer persists, especially using #radiotherapy.
This continues to be the biggest barrier to equitable #populationscreening for #earlydetection.
We must stop doing it.
#activesurveillance @uroweb.bsky.social
#Overtreatment of #prostatecancer persists, especially using #radiotherapy.
This continues to be the biggest barrier to equitable #populationscreening for #earlydetection.
We must stop doing it.
#activesurveillance @uroweb.bsky.social
Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era
This cohort study examines if rates of overtreatment of men with prostate cancer with limited life expectancy have persisted in the active surveillance era and whether overtreatment varies by tumor ri...
jamanetwork.com
November 24, 2024 at 5:38 AM
jamanetwork.com/journals/jam...
#Overtreatment of #prostatecancer persists, especially using #radiotherapy.
This continues to be the biggest barrier to equitable #populationscreening for #earlydetection.
We must stop doing it.
#activesurveillance @uroweb.bsky.social
#Overtreatment of #prostatecancer persists, especially using #radiotherapy.
This continues to be the biggest barrier to equitable #populationscreening for #earlydetection.
We must stop doing it.
#activesurveillance @uroweb.bsky.social
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
November 23, 2024 at 3:04 AM
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
Reposted by Matt Cooperberg
Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors.
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
November 21, 2024 at 6:48 AM
Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors.
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
#ProstateCancer #ActiveSurveillance #Oncology #CancerResearch
@oncoalert.bsky.social
This is not the first time. It’s not even the first time this decade! prospect.org/culture/book...
November 19, 2024 at 8:28 PM
This is not the first time. It’s not even the first time this decade! prospect.org/culture/book...
Reposted by Matt Cooperberg
To echo @dr-coops.bsky.social i thought we could thread some of the most interesting #BladderCancer papers over the last few months ... that might have missed discussion @alisonbirtle.bsky.social @bladdercancer.bsky.social .....
November 19, 2024 at 9:50 AM
To echo @dr-coops.bsky.social i thought we could thread some of the most interesting #BladderCancer papers over the last few months ... that might have missed discussion @alisonbirtle.bsky.social @bladdercancer.bsky.social .....
Nice article about our new #UroSoMe home… I’m optimistic!
But can you believe there are only 20 people running this show #bluesky??
www.nytimes.com/2024/11/17/t...
But can you believe there are only 20 people running this show #bluesky??
www.nytimes.com/2024/11/17/t...
How Bluesky, Alternative to X and Facebook, Is Handling Growth
The fledgling social media site has been flooded with new users since the election. It hasn’t all been easy.
www.nytimes.com
November 19, 2024 at 2:43 AM
Nice article about our new #UroSoMe home… I’m optimistic!
But can you believe there are only 20 people running this show #bluesky??
www.nytimes.com/2024/11/17/t...
But can you believe there are only 20 people running this show #bluesky??
www.nytimes.com/2024/11/17/t...
What’s your single favorite #prostatecancer paper of the year so far?
I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️
www.thelancet.com/journals/lan...
I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️
www.thelancet.com/journals/lan...
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study
An AI system was superior to radiologists using PI-RADS (2.1), on average, at detecting
clinically significant prostate cancer and comparable to the standard of care. Such
a system shows the potential...
www.thelancet.com
November 17, 2024 at 5:12 PM
What’s your single favorite #prostatecancer paper of the year so far?
I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️
www.thelancet.com/journals/lan...
I’ll lead with PI-CAI: big leap forward for prostate MRI through a highly collaborative AI effort. And the best part is it’s all free and *open-source*! ⭐️
www.thelancet.com/journals/lan...
Reposted by Matt Cooperberg
Ok Not really sure what I’m doing but this #ProstateCancer starter pack has been created
It is meant to be INclusive so please let me know if you know anyone who wants so “join”
@asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social
go.bsky.app/ANw3D3j
It is meant to be INclusive so please let me know if you know anyone who wants so “join”
@asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social
go.bsky.app/ANw3D3j
November 16, 2024 at 2:45 PM
Ok Not really sure what I’m doing but this #ProstateCancer starter pack has been created
It is meant to be INclusive so please let me know if you know anyone who wants so “join”
@asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social
go.bsky.app/ANw3D3j
It is meant to be INclusive so please let me know if you know anyone who wants so “join”
@asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social
go.bsky.app/ANw3D3j
Reposted by Matt Cooperberg
Great day spent on strategic planning with AUA to improve Urology clinical trial participation at both patient and provider level. Stay tuned!
@dr-coops.bsky.social
@dr-coops.bsky.social
November 16, 2024 at 10:25 PM
Great day spent on strategic planning with AUA to improve Urology clinical trial participation at both patient and provider level. Stay tuned!
@dr-coops.bsky.social
@dr-coops.bsky.social
Reposted by Matt Cooperberg
GU starter pack… started!
Let me know if you want to be added.
go.bsky.app/DtoXvaD
#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter
Let me know if you want to be added.
go.bsky.app/DtoXvaD
#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter
November 16, 2024 at 5:55 AM
GU starter pack… started!
Let me know if you want to be added.
go.bsky.app/DtoXvaD
#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter
Let me know if you want to be added.
go.bsky.app/DtoXvaD
#Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter
It was a pleasure to join Dr Geo Espinoza for a great dialog re: #prostatecancer diagnostics and related topics
Modern and Best Methods to Diagnose Prostate Cancer
youtu.be/ZLpcd-0oM0E?...
Modern and Best Methods to Diagnose Prostate Cancer
youtu.be/ZLpcd-0oM0E?...
Modern and Best Methods to Diagnose Prostate Cancer with Dr Matthew Cooperberg -EP -123
YouTube video by Dr. Geo Prostate Podcast
youtu.be
November 15, 2024 at 12:18 PM
It was a pleasure to join Dr Geo Espinoza for a great dialog re: #prostatecancer diagnostics and related topics
Modern and Best Methods to Diagnose Prostate Cancer
youtu.be/ZLpcd-0oM0E?...
Modern and Best Methods to Diagnose Prostate Cancer
youtu.be/ZLpcd-0oM0E?...